Galectins, a family of β-galactoside-binding lectins, are increasingly recognized as key players in cancer progression, inflammation, fibrosis, and immune regulation. Their ability to modulate cell adhesion, migration, proliferation, and apoptosis makes them attractive targets for therapeutic intervention. Despite the long-standing focus on carbohydrate-based inhibitors—such as lactose, thiodigalactose, and lactulose—these compounds suffer from weak binding affinity, poor bioavailability, rapid clearance, and synthetic complexity. To address these limitations, significant progress has been made in developing non-carbohydrate galectin inhibitors that offer improved pharmacological profiles while retaining high potency.
This article presents a comprehensive overview of recent advances in non-carbohydrate galectin inhibitors, emphasizing their molecular design, mechanism of action, and translational potential. A major breakthrough came with the discovery of peptide mimetics such as Anginex (57) and its optimized derivative 6DBF7 (58), which exhibit potent anti-angiogenic activity by targeting galectin-1 outside its canonical carbohydrate-binding site. NMR and structural studies revealed that these compounds bind to the hydrophobic surface of galectin-1, inducing conformational changes that disrupt its functional dimerization and interaction with cell-surface glycans. This allosteric inhibition mechanism offers advantages over competitive blockers, reducing off-target effects and resistance development.
Further innovation emerged with the identification of small-molecule inhibitors like LLS2 (64), discovered through One-Bead Two-Compound (OB2C) ultra-high-throughput screening. LLS2 binds at the dimer interface of galectin-1, interfering with its membrane localization and downstream signaling via H-Ras and K-Ras, thereby inhibiting the MAPK/ERK pathway. It demonstrated strong antitumor activity in ovarian cancer models and synergistic effects when combined with paclitaxel, highlighting its potential as a lead compound for combination therapy.
Another promising class includes heterocyclic hybrids such as coumarin-triazole and benzimidazole-triazole derivatives. Goud et al. reported a series of 22 morpholine-linked coumarin-triazole hybrids, among which compound 69 exhibited an IC50 of 0.80 ± 0.22 μM against MG-63 osteosarcoma cells. The compound induced apoptosis through mitochondrial depolarization, ROS elevation, chromatin condensation, and G0/G1 cell cycle arrest. Importantly, it significantly downregulated galectin-1 expression in a dose-dependent manner, confirming target engagement.
Similarly, novel 4,7-disubstituted coumarin derivatives showed IC50 values between 7.45 and 8.95 μM against prostate cancer lines. Radiolabeling with 18F enabled their use as PET tracers for tumor imaging, demonstrating dual functionality as both therapeutic agents and diagnostic tools.1-Acetamidonaphthalene Data Sheet These findings underscore the versatility of scaffold engineering in creating multifunctional molecules.2649400-34-8 References
The role of computational modeling in inhibitor design cannot be overstated. In silico studies using reverse docking, molecular dynamics (MD), and free energy calculations have successfully predicted binding modes and stability of compounds like bergenin (65), which forms hydrogen bonds with Asp-148, Asn-174, and Glu-184 in galectin-3, along with π–π stacking interactions. MD simulations confirmed complex stability over 50 ns, supporting its potential as a scaffold for further optimization.
Allosteric inhibition has also been validated in other systems. For instance, stapled α-helical peptides derived from phage libraries displayed Kd values as low as 0.45 μM against galectin-3, outperforming lactose by over 1,000-fold. Their enhanced stability and binding affinity stem from covalent cross-linking that locks the helical conformation, facilitating deep penetration into protein-protein interfaces.PMID:35197405
A particularly notable example is MG-257 (73), a quinoline-pyrazole hybrid identified via TR-FRET screening. It specifically inhibits the TREM2–galectin-3 interaction implicated in neuroinflammation. Fluorescence anisotropy and MD simulations revealed that its isoquinoline core remains stably bound within the active site, while the pyrazole moiety engages in critical hydrogen bonding with Glu-184. This compound delays TREM2/DAP12 signaling and reduces pro-inflammatory cytokines, positioning it as a candidate for Alzheimer’s disease therapeutics.
In summary, non-carbohydrate galectin inhibitors represent a paradigm shift in targeting glycan-mediated pathways. By leveraging fragment-based screening, rational scaffold design, and advanced computational methods, researchers have developed molecules with superior pharmacokinetic properties, higher specificity, and novel mechanisms of action. Future directions should include in vivo validation, toxicity profiling, and clinical translation of top candidates. With continued innovation, non-carbohydrate inhibitors hold immense promise not only for oncology but also for treating chronic inflammatory and neurodegenerative diseases where galectins play central roles.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
